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Background: To examine trends in the population levels of serum lipids among a Middle-Eastern adult population
with high prevalence of dyslipidemia.
Methods: A population-based cohort of adult Iranian participants, aged ≥20 years underwent four consecutive
examinations between 1999–2001 and 2008–2011. Trends in age and multivariate-adjusted mean lipid levels were
calculated using generalized estimating equations.
Results: At each of the 4 assessments, there were significant decreases in levels of total cholesterol (TC)
(multivariate-adjusted means, 5.21 vs. 4.88 mmol/L in men; 5.42 vs. 5.07 mmol/L in women), triglycerides (TGs) (2.11
vs. 1.94 mmol/L in men; 1.88 vs. 1.74 mmol/L in women), and an increase in HDL-C level in both genders (0.95 vs.
1.058 mmol/L in men; 1.103 vs. 1.246 mmol/L in women) in multivariate analyses (all Ps <0.001); however, body
mass index (BMI) significantly increased simultaneously (25.92 vs. 27.45 kg/m2 in men; 27.76 vs. 30.02 kg/m2 in
women) (P < 0.001). There were significant (P < 0.001) increases in fasting plasma glucose (FPG) levels only among
men (5.35 vs. 5.73 mmol/L). Results did not change after excluding participants that had cardiovascular disease or
used lipid lowering drugs during follow-up. There were significant decreases in the prevalence of
hypercholesterolemia, low HDL-C, hypertriglyceridemia (all Ps <0.001) during follow-up. Furthermore, the
consumption of lipid lowering drugs significantly increased (P <0.001).
Conclusion: During a 10 years follow-up, favorable trends were observed in the population levels of TC,
triglycerides, HDL-C, which could not be fully accounted for by the increase observed in the consumption of lipid
lowering drugs. These favorable trends were counterbalanced by the progressive increase in general obesity and
FPG level.
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Coronary heart disease (CHD) is one of the main causes
of mortality and morbidity worldwide, leading severe
concern that CHD will become pandemic problem [1].
Cardiovascular disease (CVD) account for 38–50% of
deaths in Iran [2]. Numerous studies have reported that
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article, unless otherwise stated.cholesterol (HDL-C) are major risk factors for coronary
heart disease [3,4]. There are also evidences to show that
high triglycerides and CHD have an association [5,6].
The prevalence of dyslipidemia between Tehranian adult
population has been reported to be high [7]. We have
recently observed that all lipid measures were significant
predictors of incident CHD among an Iranian popula-
tion aged ≥50 years in sex and multivariate-adjusted re-
gression models [8].
Trends in a lipid measure vary across different
countries; even in the same country different lipid
measures might have different trends in bothntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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studies have examined the trends in serum lipid
levels either in repeated cross-sectional time-series
[9-15] or in longitudinal cohort studies [16-18]. It
seems that the trends in the levels of total and low
density lipoprotein cholesterol (LDL-C) are favorable
in most of countries, except India, China and Japan
[9,10,12]. In a global study of trends in serum total
cholesterol in 199 countries, the mean level of total
cholesterol changed little between 1980 and 2008,
declining by less than 0.1 mmol/L per decade in
men and women. Total cholesterol decreased in the
high-income region consisting of Australasia, North
America, and western Europe, and in central and
eastern Europe while it increased in east and south-
east Asia and Pacific [19]. In a previous report on
time-trends in lipid measures among an Iranian
adult population, we observed short-term favorable
trends paralleling the increasing trend in obesity
measures, whether such favorable trends have
extended to a longer time-frame in the light ofBaseline data for the 15005 people aged
participated in the study and complete
Aged ≥ 20 years (N=103
Allocated to the control group
(N=6437)
Participants in the second examination
(N=3960)
Participants in the fourth examination
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Exclusion of participants that have not follow up measurements o
(N=1290)
Analysis of data on 4951 participants
Exclusion of participants that have cardiovascular disease at exam
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Exclusion of participants that were used lipid lowering drug exam
examinations (N=2138)
Analysis of data on 2394 participants
Figure 1 Outline of selection design of study participants.increases observed in the diabetes and obesity re-
mains to be elucidated [15,20].
Recently the fourth follow-up assessment of a large
community-based longitudinal study of a Middle East
population, the Tehran Lipid and Glucose Study (TLGS)
has been completed, herein, the trends in the population
levels of serum lipids and indices as well as trends in
prevalence of dyslipidemia among TLGS’ participants
followed for more than a decade, enabling us to investi-
gate the trends in lipid measures during the last decade.
Methods
Study design and sample
Detailed descriptions of TLGS have been reported else-
where [21]. In brief, the TLGS is a large scale, long term,
community-based prospective study performed on a
representative sample of residents of district 13 of
Tehran, the capital of Iran. The TLGS has two major
components: a cross-sectional prevalence study of non-
communicable disease and associated risk factors, imple-






≥ 3 years which
inform consent
66)
Excluded the intervention group 
(N=3929)
 lipid levels
f lipid levels at any examination
ination I or any follow up
ination I or any follow up
Kheirandish et al. Lipids in Health and Disease 2014, 13:20 Page 3 of 13
http://www.lipidworld.com/content/13/1/20prospective follow-up study. Data collection is ongoing,
designed to continue for at least 20 years, on triennial
basis.Study population
Of total of 27340 residents aged ≥ 3 years invited
by telephone call, 15005 residents participated in first
examination. Of this population those aged ≥ 20 years
(n=10366), were categorized into the cohort (n=6437)
and intervention group (n=3929), the latter to be edu-
cated for implementation of life style modifications.
After excluding intervention group, participants without
any lipid levels record in baseline (n=196), and partici-
pants without follow-up record in any examination
(n=1290), the final sample consisted of a total of 4951
individuals (2866 women) with at least 1 follow-up. In
the secondary analyses, we analyzed trends of lipid levels
in a smaller sample (2394) obtained by excluding indi-
viduals with prevalent or incident cardiovascular disease
(CVD) and current use of lipid lowering drugs
(Figure 1).
The design of the study was approved by the Ethics
Committee of the Research Institute for Endocrine
Sciences, Shahid Beheshti University of Medical Sci-
ences, and all participants provided written informed
consent.Table 1 Baseline characteristics comparison of participants w
genders*
Male
Follow up No follow up
(N = 3427) (N = 968)
Age (years) 44.03 (15.4) 44.46 (17.37)
Education‡
<6 yrs 971 (28.4) 290 (30)
6-12 yrs 1870 (54.6) 513 (53.1)
>12 yrs 582 (17) 164 (17)
Marital status‡
Single 570 (16.6) 202 (20.9)
Married 2829 (82.6) 758 (78.3)
Divorce or widow 28 (0.8) 8(0.8)
Current smoking‡ 923 (27.5) 319 (33.8)
BMI (kg/m2) 25.88 (4.07) 25.46 (4.25)
Triglycerides (mmol/L)† 156 (119) 139 (109)
HDL-C (mmol/L) 38.42 (9.36) 38.36 (9.80)
Cholesterol (mmol/L) 205.45 (43.34) 200.73 (42.68)
Abbreviations: BMI body mass, HDL-C high-density lipoprotein cholesterol, TG triglyc
*Values are presented as mean (SD) for continuous parameters.
†Median (IQ).
‡n (%).Clinical and anthropometric measurements
Subjects were interviewed by trained interviewers using
pretested questionnaires. Information on age, sex, past
medical history of CVD, medication use, smoking habits
and family history of premature CVD was collected. An-
thropometric measured including weight and waist
circumference (WC). Using standard protocols, WC
was measured by a trained individual at the level of
the umbilicus. Body mass index (BMI) was calculated
as weight in kilograms divided by height in squared
meters. Blood pressure (BP) was measured twice in a
seated position after 15 min resting using a standard
mercury sphygmomanometer. Education status was
categorized into 3 groups: 1. Illiterate/primary school
(less than 6 years); 2. Below diploma /diploma (6-12
years) and 3. Higher than diploma (more than 12 years).
Marital status was categorized as single, married and
widowed/divorced.Laboratory measurements
After 12–14 h overnight fasting, blood samples were drawn
from veins of the participitants into Vacutainer® tubes be-
tween 7.00 and 9.00 A.M. and centrifuged within 30–45
min of collection. Fasting plasma glucose (FPG) was mea-
sured by the enzymatic colorimetric glucose oxidase
method; inter-and intra-assay coefficients of variation (CV)ith and without follow-up with respect to different
Female
p-value Follow up No follow up p-value
(N = 4687) (N = 1284)
0.5 41.61 (13.85) 42.23 (16.4) 0.22
0.6 0.43
1909 (40.8) 540 (42.1)
2373 (50.7) 625 (48.8)
397 (8.5) 117 (9.1)
0.01 <0.001
496 (10.6) 197 (15.3)
3755 (80.1) 928 (72.3)
436 (9.3) 159 (12.4)
<0.001 162 (3.5) 72 (5.7) <0.001
0.006 27.40 (5.38) 27.16 (5.83) 0.22
<0.001 137 (112) 136 (110) 0.5
0.87 45.06 (11.14) 45.02 (11.42) 0.92
0.004 212.95 (48.9) 212.52 (50.84) 0.78
erides.
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A Selectra 2 autoanalyzer (Vital Scientific, Spankeren,
Netherlands) was used in the TLGS research laboratory, on
the day of blood collection, to analyze samples for serum
total cholesterol (TC) and TGs. Enzymatic colorimetric
tests were used to assay TC with cholesterol esterase and
cholesterol oxidase; for TGs, glycerol phosphate oxidase
was used. HDL-C was measured after precipitation of the
lipoprotein-B-containing lipoproteins with phosphotungstic
acid. LDL-C was calculated according to the Friedewald
formula if TGs were <4.5 mmol/l [22]. Non-HDL-C was
calculated by subtracting HDL-C from TC; TC/HDL-C and
TG/HDL-C were calculated by dividing TC and TG by
HDL-C, respectively. Both inter and intra-assay coefficients
of variation were less than 1.9, 2.1 and 3% for TC, TGs and
HDL-C, respectively in all baseline and follow-up assays of
lipid profile.
Cardiovascular disease outcome
Details of the collection of cardiovascular outcome data
have been published elsewhere [21]. In the current
study, the events targeted were the first CVD events, in-
cluding definite myocardial infarction (MI), probable MI,Table 2 Baseline characteristics participants by gender*
Male (N = 2085)
Age (years) 43.8 (15.011)
Education‡
<6 yrs 566 (27.2)
6-12 yrs 1148 (55.1)




Divorce or widow 14 (0.7)
Current smoking‡ 568 (27.9)
BMI (kg/m2) 25.73 (4.046)
Waist circumference (cm) 88.53 (11.33)
Systolic BP (mm Hg) 120.71 (18.51)
Diastolic BP (mm Hg) 78 (11.02)
TC (mmol/L) 5.3 (1.124)
HDL-C (mmol/L) 1.0 (0.24)
TG (mmol/L)† 1.75 (1.31)
Non-HDL-C (mmol/L) 4.3 (1.13)
TC/HDl-C 5.6 (1.75)
TG/HDL-C† 1.82 (1.06)
FPG (mmol/L) 5.38 (1.5)
Abbreviations: BMI body mass, BP blood pressure, FPG Fasting plasma glucose, HDL-
cholesterol, TC total cholesterol, TG triglycerides.
*Values are presented as mean (SD) for continuous parameters.
†Median (IQ).
‡n (%).unstable angina, angiographic-proven coronary heart
disease (CHD), and stroke (as defined by a new neuro-
logical deficit that lasted more than 24 h).
Definition of terms
Dyslipidemia was defined as follows: Hypercholesterol-
emia: serum TC ≥ 6.19 mmol/L; Hypertriglyceridemia:
serum TGs ≥ 2.26 mmol/L; Low HDL-C: serum HDL <
1.036 mmol/L; High non-HDL-C: serum non-HDL-C ≥
5.15 mmol/L; High TC/HDL-C ≥ 5.97; High TG /HDL-
C ≥ 2.18 [23].
Participants who had systolic blood pressure ≥ 140
mmHg or diastolic blood pressure ≥ 90 mmHg or were
on antihypertensive drugs were referred to as hyperten-
sive. Diabetes mellitus was ascertained among partici-
pants who had FPG ≥7 mmol/L or were on glucose
lowering medication. Participants who were smoking at
the time of examination were considered as current
smokers.
Statistical analysis
Continuously-distributed variables were described by
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bution was highly positively skewed. All analyses were
performed separately for males and females. The statis-
tical significance of the differences in mean levels of
normally distributed variables was examined using the
t-test. The Kruskal-Wallis test was used for TGs. Chi-
square test was performed to test univariate statistical
association between categorical variables at baseline.
All baseline characteristics including age, educational
level, marital status, smoking, systolic blood pressure,
WC, diabetes, and history of CVD, were included in the
logistic model with participation as the outcome. TheTable 3 Characteristics of participants by gender at examinat
Exam 1 (1999–2001) Exam 2 (2
Male
Age (years) 43.8 (15.011) 47.50 (14.1
BMI (kg/m2) 25.73 (4.046) 26.57 (5.22
WC (cm) 88.53 (11.33) 94.60 (10.6
Systolic BP (mm Hg) 120.71 (18.51) 119.2 (17.5
Diastolic BP (mm Hg) 78 (11.02) 75.58 (10.9
TC (mmol/L) 5.3 (1.124) 5.02 (0.99)
HDL-C (mmol/L) 1.0 (0.24) 0.9 (0.21)
TG (mmol/L)† 1.75 (1.31) 2.05 (1.38)
Non-HDL-C (mmol/L) 4.3 (1.13) 4.11 (0.96)
TC/HDL-C 5.6 (1.75) 5.83 (1.63)
TG/HDL-C† 1.82 (1.06) 2.50 (1.86)
FPG (mmol/L) 5.38 (1.5) 5.56 (1.58)
Current smoking‡ 568 (27.9) 489 (23.5)
Lipid drug‡ 34 (1.66) 49 (3.2)
Female
Age (year) 41.61 (13.77) 45.5 (13.21
BMI (kg/m2) 27.51 (5.2) 29 (4.8)
WC (cm) 87.62 (12.8) 92.17 (12.2
Systolic BP (mm Hg) 118.45 (18.95) 116.9 (19.4
Diastolic BP (mm Hg) 77.82 (10.43) 75.51 (10.1
TC (mmol/L) 5.51 (1.28) 5.23 (1.14)
HDL-C (mmol/L) 1.166 (0.30) 1.05 (0.26)
TG (mmol/L)† 1.54 (1.24) 1.85 (1.16)
Non-HDL-C (mmol/L) 4.34 (1.28) 4.17 (1.13)
TC/HDL-C 5.0 (1.53) 5.24 (1.7)
TG/HDL-C† 1.35 (1.34) 1.97 (1.63)
FPG (mmol/L) 5.45 (1.97) 5.57 (1.86)
Current smoking‡ 118 (4.2) 159 (5.5)
Lipid drug‡ 131 (4.64) 109 (4.83)
Abbreviations: BMI body mass index, BP blood pressure, Exam examination cycle, FP
cholesterol, non HDL-C non-high-density lipoprotein cholesterol, TG triglycerides, W
*Values are presented as mean (SD) unless otherwise indicated.
†Median (IQ).
‡n (%).probability of participation was estimated using logistic
model and used as a propensity score. We added this
propensity score to the longitudinal models as a covari-
ate and examined if the probability of participation was
associated with trend in lipid levels [24]. Furthermore
we adjusted propensity score for all baseline characteris-
tics in all four examination cycles and the parameter
estimates remained essentially unchanged. Therefore,
the selection bias is unlikely to have affected our
estimations.
Trends of TC, LDL-C, HDL-C, and TGs levels were
primary lipid measures of interest for the currention cycle (baseline + 3 follow ups)*
002–2005) Exam 3 (2005–2008) Exam 4 (2008–2011)
5) 50.57 (14.14) 54.00 (14.16)
) 27 (5.25) 27.23 (6.4)
5) 96.18 (10.23) 97.52 (10.76)
5) 120.93 (18.91) 122.73 (18.26)
1) 76.57 (9.97) 79.91 (10.92)
4.97 (0.96) 4.96 (1.05)
0.96 (0.21) 1.11 (0.24)
2.01 (1.23) 1.9 (1.37)
4.00 (0.95) 3.83 (0.96)
5.40 (1.5) 4.63 (1.35)
2.29 (1.7) 1.86 (1.46)
5.51 (1.64) 5.86 (1.8)
553 (26.5) 555 (26.6)
62 (3.77) 164 (9.63)
) 48.46 (13.13) 51.95 (13.15)
29.2 (4.8) 30.23 (15)
8) 91.71 (12.36) 96.5 (12)
2) 115.18 (19.92) 118.87 (21.08)
8) 73.05 (10.34) 76.68 (11.14)
5.17 (1.07) 5.2 (1.08)
1.13 (0.27) 1.31 (0.28)
1.81 (1.06) 1.73 (0.96)
4.04 (1.46) 3.88 (1.08)
4.8 (1.46) 4.11 (1.19)
1.8 (1.38) 1.45 (1.07)
5.55 (1.96) 5.9 (2.08)
141 (4.9) 160 (5.6)
152 (6.5) 296 (12.38)
G Fasting plasma glucose, TC total cholesterol, HDL-C high-density lipoprotein
C waist circumference.
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tion levels of non-HDL-C, TC/HDL-C and TG/HDL-C
ratio as well. Time trends in the population levels of the
lipid measures, were examined using generalized esti-
mating equations (GEE). The GEE method facilitates
analysis of longitudinal data or repeated measures on
dependent variables of many different distributions,
mainly binary data [25]. GEE is a statistical technique
enabling researchers to restrict modeling to the first mo-
ment which require only the correct working correlation
matrix which specified the univariate marginal distribu-
tions [26]. Analysis with an exchangeable correlation
structure with only random intercept was designed for
the current data. Such an approach enabled us to ac-
count for the correlation among observations following
assessment of each examination cycle. Models were de-
veloped at two hierarchial levels; age-adjusted (adjusting
for age, propensity score and examination cycle) and
multivariate-adjusted (adjusting for age, examination
cycle, propensity score, BMI, current smoking, diabetes,
hypertension and total cholesterol level [in analysis of
HDL-C and TG]). Trends in BMI and FPG were also ex-
amined in both age and multivariate-adjusted models.
We also compared the trends in prevalence of high
cholesterol, high TGs, low HDL-C, high non-HDL-C,
high TC/HDL-C and high TG/HDL-C. The significanceTable 4 Age-adjusted mean levels* of fasting lipids, FPG and
Exam 1 (1999–2001) Exam 2 (2002–2005)
Male
TC† 5.22 (5.21-5.23) 5.12 (5.10-5.13)
HDL-C† 0.943 (0.942-0.944) 0.982 (0.981-0.983)
TG† 2.08 (2.07-2.09) 2.01 (2.00-2.02)
Non-HDL-C† 4.28 (4.27-4.29) 4.13 (4.12-4.14)
TG/HDL-C 2.45 (2.44-2.47) 2.28 (2.27-2.30)
TC /HDL-C 5.81 (5.80-5.81) 5.48 (5.47-5.50)
FPG† 5.35 (5.32-5.37) 5.54 (5.51-5.57)
BMI (kg/m2) 25.88 (25.85-25.92) 26.36 (26.32-26.4)
Female
TC† 5.42 (5.40-5.44) 5.35 (5.33-5.37)
HDL-C† 1.1004 (1.1002-1.1007) 1.1486 (1.1484-1.1487)
TG† 1.86 (1.84-1.87) 1.84 (1.83-1.86)
Non-HDL-C† 4.32 (4.30-4.34) 4.2 (4.18-4.22)
TG/HDL-C 1.9 (1.88-1.91) 1.81 (1.80-1.82)
TC/HDL-C 5.19 (5.17-5.21) 4.93 (4.91-4.95)
FPG† 5.47 (5.44-5.49) 5.63 (5.60-5.66))
BMI (kg/m2) 27.73 (27.63-27.78) 26.64 (28.57-28.7)
Abbreviations: BMI body mass index, Exam examination cycle, FPG fasting plasma gl
lipoprotein cholesterol, TC total cholesterol, TG triglycerides.
*Values are age adjusted means (95% confidence intervals) from generalized estima
propensity score and examination cycle.
†mmol/L.of trends in the proportions was examined by pooled lo-
gistic regression. All the analyses were repeated in the
smaller sample (i.e. excluding individuals with prevalent
or incident CVD and current use of lipid lowering
drugs).
P-values < 0.05 were considered significant. All ana-
lyses were performed using SAS statistical software (ver.
9.2, SAS Institute, Car, NC, USA).Results
The comparison between baseline characteristics of par-
ticipants with and without follow-up disclosed that the
followed men had higher mean levels of TC, TGs and
BMI, although they had lower rate of smoking. There
was no difference in the lipid status between the
followed versus non followed women; however, the
followed participants had lower rate of smoking
(Table 1).
In the baseline examination, male participants were
older, more likely to be single, being smokers, and had
higher educational levels, as well as higher TGs, TC/
HDL-C and TG/HDL-C levels compared to female par-
ticipants; however mean BMI, total and HDL-C levels
were higher in female participants in comparison with
male ones (Table 2).BMI by examination cycle in large sample
Exam 3 (2005–2008) Exam 4 (2008–2011) p-value for trend
4.99 (4.95-5.00) 4.88 (4.87-4.90) <0.001
1.016 (1.015-1.017) 1.052 (1.051-1.053) <0.001
1.96 (1.95-1.97) 1.90 (1.89-1.91) <0.001
3.97 (3.96-3.98) 3.82 (3.81-3.83) <0.001
2.15 (2.14-2.16) 2.00 (1.99-2.01) <0.001
5.17 (5.16-5.18) 4.85 (4.84-4.86) <0.001
5.62 (5.59-5.64) 5.73 (5.71-5.75) <0.001
26.87 (26.83-26.9) 27.37 (27.33-27.40) <0.001
5.19 (5.17-5.21) 5.07 (5.05-5.09) <0.001
1.1960 (1.195-1.197) 1.2450 (1.244-1.246) <0.001
1.76 (1.75-1.77) 1.71 (1.69-1.72) <0.001
4 (3.98-4.02) 3.83 (3.81-3.85) <0.001
1.66 (1.64-1.70) 1.53 (1.52-1.54) <0.001
4.6 (4.57-4.61) 4.28 (4.26-4.30) <0.001
5.63 (5.61-5.66) 5.78 (5.75-5.81) 0.37
29.24 (29.18-29.3) 29.94 (29.88-30.0) <0.001
ucose, HDL-C high-density lipoprotein cholesterol, non HDL-C non-high-density
ting equations to account for correlated observations. Adjusted for age,
Kheirandish et al. Lipids in Health and Disease 2014, 13:20 Page 7 of 13
http://www.lipidworld.com/content/13/1/20The baseline as well as follow-up characteristics of
three assessments are shown in Table 3 in each gender.
At baseline examination the mean age of participants
were 43.8 (15.011) and 41.61 (13.77) years for men and
women, respectively. Mean BMI was 25.73 (4.046) and
27.51(5.2) kg/m2 in men and women, respectively.
As presented in the Tables 4 and 5, we observed a
statistically significant decrease in the age and
multivariate-adjusted levels of total and non-HDL
cholesterol, TC/HDL-C and TG/HDL-C, as well as
TGs for both genders (p-value for TGs trend was
marginally significant for men). In contrast there was
a significant increase in HDL-C levels across follow-
up examinations in both men and women (all P-
values <0.001). Meanwhile, the results demonstrated
a significant increase in the population levels of BMI
(in both genders) and FPG (only among men) in the
same time frame in both genders.
Table 6 show the time trends in the age and
multivariate-adjusted prevalence rate of different as-
pects of dyslipidemia in the large sample. During the
study, in both gender, there were significant de-
creases in the prevalence of hypercholesterolemia,Table 5 Multivariate-adjusted mean levels* of fasting lipids, F
Exam 1 (1999–2001) Exam 2 (2002–2005)
Male
TC† 5.21 (5.20-5.22) 5.13 (5.12-5.15)
LDL-C† 3.82 (3.81-3.83) 3.73 (3.72-3.74)
HDL-C† 0.95 (0.94-0.95) 0.97 (0.96-0.98)
TG† 2.11 (2.08-2.14) 1.96 (1.92-1.99)
Non-HDL-C† 4.26 (4.25-4.28) 4.15 (4.14-4.17)
TG/HDL 2.43 (2.41-2.46) 2.31 (2.3-2.34)
TC/HDL 5.77 (5.75-5.8) 5.52 (5.5-5.54)
FPG† 5.35 (5.32-5.37) 5.54 (5.51-5.57))
BMI (kg/m2) 25.92 (25.87-25.97) 26.3 (26.23-26.35)
Female
TC† 5.42 (5.39-5.43) 5.37 (5.34-5.4)
LDL-C† 3.90 (3.88-3.92) 3.81 (3.79-3.83)
HDL-C† 1.103 (1.101-1.104) 1.140 (1.130-1.142)
TG† 1.88 (1.86-1.91) 1.80 (1.77-1.83)
Non-HDL-C† 4.31 (4.29-4.33) 4.22 (4.20-4.24)
TG/HDL-C 1.88 (1.87-1.90) 1.82 (1.80-1.84)
TC/HDL-C 5.20 (5.17-5.21) 4.95 (4.93-4.98)
FPG† 5.47 (5.44-5.49) 5.63 (5.60-5.66)
BMI (kg/m2) 27.76 (27.7-27.82) 28.64 (28.56-28.71)
Abbreviations: BMI body mass index, Exam examination cycle, FPG fasting plasma gl
cholesterol, non HDL-C non-high-density lipoprotein cholesterol, TC total cholestero
*Values are age adjusted means (95% confidence intervals) from generalized estima
propensity score, examination cycle, BMI, current smoking, hypertension, Diabetes (
covariates from the examination in question.
†mmol/L.hypertriglyceridemia, low HDL-C, high non-HDL-C,
high TC/HDL-C and high TG/HDL-C. Furthermore
consumption of lipid lowering drugs significantly
(p < 0.001) increased in both genders.
As ancillary analyses we repeated all analyses among
individuals without CVD who were not on lipid lowering
drugs and observed that the results remained essentially
unchanged in both age and multivariate-adjusted models
(Tables 7, 8 and 9).Discussion
Using a large cohort of a Middle Eastern adults
population, we demonstrated favorable time trends
in the population levels of total cholesterol, HDL-C,
non-HDL-C, TG, TG/HDL-C and TC/HDL-C among
both genders during 10 years follow up. Such favor-
able trends in lipids levels and ratios could not be
fully accounted for by the significant increase in
consumption of lipid lowering drugs. In contrast,
however, population levels of general adiposity and
FPG have increased in both genders potentially lead-
ing to long term risk of cardiovascular disease.PG and BMI by examination cycle in large sample
Exam 3 (2005–2008) Exam 4 (2008–2011) p-value for trend
5.00 (4.99-5.01) 4.88 (4.87-5.00) <0.001
3.58 (3.57-3.59) 3.43 (3.42-3.45) <0.001
1.013 (1.010-1.017) 1.058 (1.055-1.062) <0.001
1.93 (1.90-1.96) 1.94 (1.91-1.98) 0.057
3.98 (3.97-4.0) 3.82 (3.80-3.83) <0.001
2.15 (2.12-2.17) 2.00 (1.97-2.03) <0.001
5.18 (5.16-5.2) 4.84 (4.81-4.86) <0.001
5.62(5.59-5.64) 5.73 (5.71-5.75) <0.001
26.78 (26.72-26.84) 27.45 (27.4-27.51) <0.001
5.18 (5.16-5.20) 5.07 (5.04-5.06) <0.001
3.61 (3.59-3.63) 3.46 (3.44-3.48) <0.001
1.039 (1.037-1.194) 1.246 (1.241-1.251) <0.001
1.71 (1.68-1.73) 1.74 (1.71-1.77) <0.001
3.98 (3.96-4.00) 3.82 (3.80-3.85) <0.001
1.63 (1.61-1.65) 1.54 (1.51-1.57) <0.001
4.57 (4.56-4.60) 4.28 (4.25-4.32) <0.001
5.63 (5.61-5.66) 5.78 (5.75-5.81) 0.37
29.11 (29.05-29.18) 30.02 (29.95-30.10) <0.001
ucose, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein
l, TG triglycerides.
ting equations to account for correlated observations. Adjusted for age,
except for FPG) and total cholesterol (in analyses of HDL-C and TGs), using























High cholesterol 18.3 14.9 11.7 9.2 <0.001 24.8 22.1 17.3 14.2 <0.001
Low HDL-C 72.2 66.4 60.8 54.6 <0.001 46.2 39.4 32.9 27.1 <0.001
High Triglycerides 33.1 30.1 27.8 25.4 <0.001 26.0 25.2 22.6 21.0 <0.001
High Non-HDL-C 20.3 15.8 11.9 9.0 <0.001 23.1 19.2 13.8 10.3 <0.001
High TG/HDL-C 40.2 44.3 38.4 25.4 <0.001 28.3 25.9 22.3 19.6 <0.001
High TC /HDL-C 37.6 42.5 30.3 14.7 <0.001 26.8 21.1 14.9 10.7 <0.001
Lipid drug (%) 1.4 2.9 5.0 8.8 <0.001 3.6 5.8 7.8 11.2 <0.001
Multivariate adjusted‡
High cholesterol 18.1 15.2 11.8 9.4 <0.001 24.5 22.5 17.2 14.1 <0.001
Low HDL-C 71.0 67.8 61.2 53.6 <0.001 45.4 40.6 33.1 26.5 <0.001
High Triglycerides 33.7 29.1 27.2 26.5 <0.001 26.6 24.4 21.3 21.9 <0.001
High Non-HDL-C 19.9 16.2 12.1 9.0 <0.001 22.9 19.7 13.6 10.2 <0.001
High TG/HDL-C 32.2 39.4 34.1 29.7 <0.001 28.0 26.8 21.8 19.5 <0.001
High TC /HDL-C 41.3 34.4 26.0 19.1 <0.001 26.7 21.8 14.8 10.6 <0.001
Lipid drug (%) 1.5 2.9 4.8 9.0 <0.001 3.7 6.1 7.6 11.4 <0.001
Abbreviations: Exam examination cycle, HDL-C high-density lipoprotein cholesterol, non HDL-C non-high-density lipoprotein cholesterol, TC total cholesterol, TG triglycerides.
Definitions: High cholesterol ≥6.19 mmol/L; Low HDL-C <1.036 mmol/L; High Triglycerides ≥2.26 mmol/L; High Non-HDL-C ≥5.15 mmol/L; High TG/HDL-C ≥2.18; High TC /HDL-C ≥5.97.
*Values are age and multivariate adjusted percentage from pooled logistic regressions including examination cycle to account for correlated observations.
†Adjusted for age, propensity score, and examination cycle.






















Table 7 Age-adjusted mean levels* of fasting lipids, FPG and BMI by examination cycle in small sample
Exam 1 (1999–2001) Exam 2 (2002–2005) Exam 3 (2005–2008) Exam 4 (2008–2011) p-value for trend
Male
TC† 5.14 (5.13-5.16) 5.07 (5.06-5.09) 5.00 (4.98-5.01) 4.93 (4.91-4.94) <0.001
HDL-C† 0.937 (0.935-0.938) 0.976 (0.975-0.978) 1.015 (1.014-1.017) 1.055 (1.053-1.056) <0.001
TG† 1.97 (1.96-1.98) 1.94 (1.92-1.95) 1.91 (1.88-1.92) 1.87 (1.86-1.89) <0.001
Non-HDL-C† 4.20 (4.19-4.22) 4.09 (4.08-4.10) 3.97 (3.96-3.99) 3.86 (3.85-3.87) <0.001
TG/HDL-C 2.33 (2.31-2.34) 2.21 (2.19-2.22) 2.08 (2.07-2.10) 1.96 (1.95-1.98) <0.001
TC/HDL-C 5.74 (5.73-5.76) 5.46 (5.44-5.47) 5.16 (5.15-5.18) 4.88 (4.86-4.9) <0.001
FPG† 5.14 (5.12-5.16) 5.30 (5.28-5.32) 5.45 (5.44-5.47) 5.62 (5.60-5.63) 0.014
BMI (kg/m2) 25.85 (25.79-25.9) 26.36 (26.31-26.41) 26.85 (26.8-26.91) 27.37 (27.32-27.43) <0.001
Female
TC† 5.19 (5.16-5.21) 5.14 (5.12-5.17) 5.09 (5.07-5.11) 5.05(5.03-5.08) <0.001
HDL-C† 1.0945 (1.094-1.095) 1.149 (1.148-1.150) 1.203 (1.202-1.204) 1.258 (1.257-1.259) <0.001
TG† 1.63 (1.62-1.65) 1.62 (1.61-1.64) 1.61 (1.59-1.62) 1.60 (1.59-1.61) <0.001
Non-HDL-C† 4.09 (4.07-4.11) 4.00 (3.97-4.02) 3.89 (3.88-3.91) 3.80 (3.77-3.82) <0.001
TG/HDL-C 1.64 (1.63-1.66) 1.57 (1.56-1.58) 1.5 (1.48-1.5) 1.42 (1.40-1.43) <0.001
TC/HDL-C 4.97 (4.95-5.00) 4.72 (4.70-4.74) 4.46 (4.44-4.48) 4.21 (4.19-4.23) <0.001
FPG† 5.09 (5.07-5.11) 5.22 (5.20-5.24) 5.34 (5.32-5.36) 5.48 (5.46-5.50) 0.014
BMI (kg/m2) 27.43 (27.35-27.5) 28.16 (28.08-28.23) 28.81 (28.74-28.9) 29.50 (29.43-29.58) <0.001
Abbreviations: BMI body mass index, FPG fasting plasma glucose, exam examination cycle, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, non
HDL-C non high-density lipoprotein cholesterol, TG triglycerides.
*Values are age adjusted means (95% confidence intervals) from generalized estimating equations to account for correlated observations. Adjusted for age,
propensity score and examination cycle.
†mmol/L.
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http://www.lipidworld.com/content/13/1/20Cardiovascular disease has long been known to be
a multi-factorial disease. In 1948, the Framingham
Heart Study embarked on an ambitious project in
health research to identify the common factors that
contribute to cardiovascular disease [27], over the
years, careful monitoring of the Framingham Study
population has led to the identification of the major
CVD risk factors among which lipid measures have
been widely investigated [28,29]. Several initiatives
have been launched in different countries to reduce
the burden of CVD by reducing the level of its risk
factors [30-32]. As such, the important question to
be answered would be whether these findings could
be translated to better risk factor levels in the popu-
lation [33]. Perceiving this need, several studies have
attempted to explore the time trends in the CVD
risk factors in the populations of different ethnic
groups. Favorable trends in the lipid measures have
been documented by large studies conducted in
European as well as North American populations
[28,34,35]. However, the effects of these favorable
trends on the population burden of CVD have
paralleled the increasing trends in the obesity and
diabetes [36,37]. As a consequence, the favorable
trends in the CVD morbidity and mortality leveledoff at beginning of the 21st century [11,35]. Middle
Eastern population has been estimated to harbor a
great fraction of the world’s burden of diabetes and
obesity [20,38]. In fact, while America have been es-
timated to spend more than half of the global health
expenditure on diabetes, less than 10% of the global
health expenditure will be spent in the low and
middle-income countries [39]. Therefore, resorting to
controlling other risk factors that are more amenable
to treatment and prevention continues to be the
best policy to stopping CVD. We demonstrated sta-
tistically significant and clinically meaningful favor-
able trends in the population levels of the lipid measures
over the last decade, finding that did not change after
multivariate adjustment and elimination of lipid lowering
drugs users. The desirable trends for lipid measures in
our population is compatible with those of other studies
using cross-sectional surveys [9-11,14] and prospective
studies [13,16-18] as well.
We observed an increase in the population levels of
HDL-C simultaneously with decline in triglycerides
levels, a finding in agreement with results of the Fra-
mingham study [13] and in contrast to those of other
studies [9,10,12], showing simultaneous increases in TC,
TGs and decreasing HDL-C.
Table 8 Multivariate-adjusted mean levels* of fasting lipids, FPG and BMI by examination cycle in small sample
Exam 1 (1999–2001) Exam 2 (2002–2005) Exam 3 (2005–2008) Exam 4 (2008–2011) p-value for trend
Male
TC† 5.13 (5.12-5.15) 5.08 (5.06-5.1) 5.00 (4.99-5.2) 4.93 (4.91-4.95) <0.001
HDL-C† 0.940 (0.930-0.950) 0.970 (0.900-0.980) 1.012 (1.008-1.016) 1.058 (1.053-1.060) <0.001
TG† 1.97 (1.95-1.99) 1.95 (1.93-1.98) 1.91 (1.88-1.94) 1.89 (1.86-1.91) <0.001
Non-HDL-C† 4.19 (4.17-4.21) 4.11 (4.09-4.13) 3.99 (3.97-4.00) 3.86 (3.84-3.88) <0.001
TG/HDL-C† 2.32 (2.29-2.35) 2.22 (2.19-2.26) 2.10 (2.07-2.13) 1.96 (1.93-1.99) <0.001
TC/HDL-C 5.72 (5.69-5.75) 5.48 (5.45-5.51) 5.19 (5.16-5.22) 4.86 (4.83-4.90) <0.001
FPG † 5.14 (5.12-5.16) 5.30 (5.28-5.32) 5.45 (5.44-5.47) 5.62 (5.60-5.63) 0.048
BMI, (kg/m2) 25.91 (25.84-25.99) 26.3 (26.22-26.37) 26.78 (26.7-26.86) 27.45 (27.35-27.53) <0.001
Female
TC† 5.18 (5.15-5.20) 5.15 (5.13-5.18) 5.09 (5.06-5.11) 5.05 (5.03-5.07) <0.001
HDL-C† 1.094 (1.092-1.096) 1.144 (1.141-1.146) 1.202 (1.199-1.204) 1.256 (1.254-1.259) <0.001
TG† 1.62 (1.60-1.64) 1.63 (1.61-1.65) 1.59 (1.57-1.61) 1.60 (1.58-1.62) <0.001
Non-HDL-C† 4.08 (4.06-4.11) 4.01 (3.98-4.03) 3.88 (3.86-3.91) 3.80 (3.77-3.82) <0.001
TG/HDL-C† 1.63 (1.61-1.65) 1.6 (1.57-1.60) 1.47 (1.45-1.49) 1.42 (1.40-1.44) <0.001
TC/HDL-C 4.96 (4.94-5.00) 4.75 (4.72-4.77) 4.46 (4.43-4.48) 4.21 (4.19-4.23) <0.001
FPG † 5.10 (5.08-5.12) 5.24 (5.21-5.26) 5.34 (5.31-5.36) 5.50 (5.48-5.50) 0.05
BMI, (kg/m2) 27.46 (27.38-27.54) 28.15 (28.07-28.23) 28.73 (28.65-28.81) 29.58 (29.5-29.67) <0.001
Abbreviations: BMI body mass index, exam examination cycle, FPG fasting plasma glucose, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C
high-density lipoprotein cholesterol, non HDL-C non high-density lipoprotein cholesterol, TG triglycerides.
*Values are age adjusted means (95% confidence intervals) from generalized estimating equations to account for correlated observations. Adjusted for age,
propensity score, examination cycle, BMI, current smoking, hypertension, Diabetes (except for FPG) and total cholesterol (in analyses of HDL-C and TGs), using co-
variates from the examination in question.
†mmol/L.
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http://www.lipidworld.com/content/13/1/20In our study the prevalence of high cholesterol de-
cline about 48% and 42% in men and women re-
spectively, while the percentage of US adults with
high total cholesterol decline by 27% between 1999
and 2010; furthermore it was reported that about
12% of female participants and 31% of male partici-
pants had low HDL-C [14]. However, in our adult
population the prevalence of low HDL-C was 52%
for men and 26% for women, despite decreasing
trend in low HDL-C, dyslipidemia still has a higher
prevalence, compared to U.S adults.
Although changes in nutritional habits [40,41],
physical activity and endurance exercise [42,43] are
all known to be among important determinants of
serum lipid levels; the decreasing trends in lipid
levels in our population could hardly be explained
by life style changes (i.e. physical activity), since it
was shown that low physical activity is common in
Iranian population [44,45]. It has been shown, how-
ever, that over 30% of Iranian families are now con-
suming less hydrogenated oil than they did in the
past [46,47], that could possibly explain the favorable
lipid trend in TLGS population during recent years.
In line with our findings, cross-sectional Nationalstudies conducted by Ministry of Health and Medical
Education among Iranian adult population in whole
country, showed significant decrease in level of
high total cholesterol (Etemad K., Center for Non-
communicable Diseases Control, Ministry of Health
and Medical Education, Tehran, Iran, unpublished
observations).
Another factor that affected serum lipids is cigarette
smoking. Craig et al. in a meta-analysis about effect of
smoking on cardiovascular risk factors demonstrated that
compared with non-smokers, cigarettes smokers had sig-
nificantly higher TC, TG and lower concentrations of
HDL-C [48]. The review study in field of smoking between
1991 and 2007 in Iran showed that during these years
smoking did not increased, which might justify the favor-
able trend in HDL-C level of our population [49].
Our study has both strengths and limitations. The
strengths of the current study lie in its design as a
long term community-based prospective study con-
ducted on a large sample of Middle Eastern men
and women, a region where data on secular trends
in the lipid levels is lacking, also lipid profile com-
ponents were measured rather than self-reported.
Our findings need to be interpreted in light of its























High cholesterol 15.6 13.2 11.2 9.4 <0.001 18.0 16.4 14.6 13.4 <0.001
Low HDL-C 72.4 66.7 60.5 53.8 <0.001 46.8 39.2 32.1 25.7 <0.001
High Triglycerides 31.2 27.9 27.3 24.6 <0.001 18.3 17.1 18.1 16.8 <0.001
High Non-HDL-C 17.3 13.9 11.1 8.8 <0.001 16.1 13.1 10.4 8.4 <0.001
High TG/HDL-C 42.6 38.0 33.7 29.4 <0.001 21.4 19.5 17.5 15.9 <0.001
High TC/HDL-C 40.4 32.2 24.9 18.8 <0.001 21.4 16.1 11.7 8.6 <0.001
Multivariate adjusted‡
High cholesterol 15.5 13.4 11.4 9.7 <0.001 17.7 16.6 14.7 13.5 <0.001
Low HDL-C 71.7 67.0 60.9 53.0 <0.001 42.2 40.0 32.1 25.4 <0.001
High Triglycerides 31.1 28.0 27.6 24.7 <0.001 18.1 17.1 17.9 16.6 <0.001
High Non-HDL-C 17.0 14.2 11.3 9.0 <0.001 15.9 13.4 10.4 8.5 <0.001
High TG/HDL-C 42.1 38.7 34.8 29.4 <0.001 21.2 19.9 17.2 15.9 <0.001
High TC/HDL-C 39.8 33.0 25.4 18.6 <0.001 21.2 16.5 11.7 8.4 <0.001
Abbreviations: exam examination, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, non HDL-C non high-density lipoprotein cholesterol, TG triglycerides.
Definitions: High cholesterol ≥6.19 mmol/L; Low HDL-C <1.036 mmol/L; High Triglycerides ≥2.26 mmol/L; High Non-HDL-C ≥5.15 mmol/L; High TG/HDL-C ≥2.18; High TC /HDL-C ≥5.97.
*Values are age and multivariate adjusted percentage from pooled logistic regressions including examination cycle to account for correlated observations.
†Adjusted for age, propensity score, and examination cycle.
‡Adjusted for age, propensity score, examination cycle, BMI, current smoking, hypertension, Diabetes (except for FPG) and total cholesterol (in analyses of HDL-C and TGs), using covariates from the examination in
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http://www.lipidworld.com/content/13/1/20limitations as is inherent to any prospective study
[13]. First, survivor bias might have biased favorable
trends towards overestimated values, i.e. individuals
with possible unfavorable changes in their lipid
levels might have died and thus been excluded from
repeated measurements. Second, as any cohort study
we cannot rule out healthy cohort effect i.e. the pos-
sibility of the effect of knowledge about the serum
lipids might have affected the lifestyle or lipid drugs
consumption in the participants, leading to the fa-
vorable trends in lipid levels. Third, we did not have
any systematic data on the trends of nutritional be-
havior, physical activity and knowledge of the pri-
mary prevention in our population, consequently it
is not possible to test the hypothesis that whether
the trends observed could be attributable to changes
in physical activity or nutrition status. Forth, the re-
sults obtained in the current study might not applic-
able to certain age groups including younger (less
than 20 years) and older (over than 75 years) ones.
Finally, our population was selected from middle-
aged Middle East Caucasians and therefore we can-
not make inferences beyond a similar group.
Conclusion
The main findings in this study include an observed
decrease in total cholesterol, LDL-C, triglyceride
levels as well as TC/HDL-C and TG/HDL-C in an
adult Iranian population during the period of 1999–
2001 until 2008–2011.Overall the trends of general
obesity and FPG level were observed to have in-
creased. The net effect of such trends on the CVD
burden warrants further investigations.
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